SG Americas Securities LLC Has $2.36 Million Stake in Halozyme Therapeutics, Inc. $HALO

SG Americas Securities LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,093 shares of the biopharmaceutical company’s stock after acquiring an additional 9,260 shares during the quarter. SG Americas Securities LLC’s holdings in Halozyme Therapeutics were worth $2,362,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of HALO. Root Financial Partners LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth about $25,000. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. Richardson Financial Services Inc. increased its position in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 198 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics in the second quarter valued at approximately $32,000. Finally, Clearstead Advisors LLC raised its stake in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $64.49 on Friday. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89. The company has a market cap of $7.64 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 0.26 and a beta of 1.03. The company has a 50 day moving average of $69.94 and a 200-day moving average of $69.33. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business’s revenue was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 earnings per share. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on HALO shares. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $78.56.

Insiders Place Their Bets

In other news, COO Cortney Caudill sold 8,857 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares in the company, valued at approximately $477,200.20. This trade represents a 55.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the transaction, the director directly owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 110,857 shares of company stock worth $7,785,087 over the last three months. Insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.